The effect of a selective cyclooxygenase-2 (COX-2) inhibitor on the proliferation rate of retinoblastoma cell lines

Eye

Volumn 20, Issue 5, 2006, Pages 598-601

  de Souza Filho, J Pessoa ^a,b,d   Correa, Z M S ^a,c   Marshall, J C ^a   Anteka, E ^a   Coutinho, A B ^a,b   Martins, M C ^b   Burnier Jr , M N ^a  

^a MCGILL UNIVERSITY   (Canada)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c Retina and Oncology Services   (Brazil)

^d NONE   (Canada)

Author keywords

Cell lines; COX 2; Immunocytochemistry; Nepafenac; Retinoblastoma

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AMFENAC; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NEPAFENAC; UNCLASSIFIED DRUG;

ARTICLE; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PROTEIN EXPRESSION; RECORDING; RETINOBLASTOMA; STATISTICAL SIGNIFICANCE; STUDENT T TEST; TUMOR CELL CULTURE; TUMOR CELL LINE; TUMOR GROWTH; WESTERN BLOTTING;

EID: 33646392497     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6701938     Document Type: Article

References (19)

1. Deegan WF. Emerging strategies for the treatment of retinoblastoma. Curr Opin Ophthalmol 2003; 14(5): 291-295.
2. Burnier MN, McLean IW, Zimmerman LE, Rosenberg SH. Retinoblastoma. The relationship of proliferating cells to blood vessels. Invest Ophthalmol Vis Sci 1990; 31(10): 2037-2040.
3. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM et al. Antiangiogenic and antitumor activities of cydooxygenase-2 inhibitors. Cancer Res 2000; 60(5): 1306-1311.
4. Karim MM, Hayashi Y, Inoue M, Imai Y, Ito H, Yamamoto M. Cox-2 expression in retinoblastoma. Am J Ophthalmol 2000; 129(3): 398-401.
5. Mendez MC, Fernandes L, Caissie AL, Callejo SA, Burnier MN. Cyclooxygenase-2 (COX-2) expression in retinoblastoma. Invest Ophthalmol Vis Sci 2002; 43, ARVO B579.
6. Mendez MC, Fernandes L, Caissie AL, Callejo SA, Burnier Jr MN. Cyclooxygenase-2 (COX-2) Expression In Retinoblastoma. Invest Ophthalmol Vis Sci 2002; 43(Suppl): E-Abstract 2582.
7. Shono T, Tofilon PJ, Burner JM, Owolabi O, Lang FF. Cyclooxygenase-2 expression in human gliomas: Prognostic significance and molecular correlations. Cancer Res 2001; 61(11): 4375-4381.
8. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58(3): 409-412.
9. Dempke W, Rie C, Grothey A, Schmoll HJ. Cyclooxygenase-2: A novel target for cancer chemotherapy? J Cancer Res Clin Oncol 2001; 127(7): 411-417.
10. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 1997; 39: 1-20.
11. Kawamori T, Wakabayashi K. COX-2 and prostanoid receptors: Good targets for chemoprevention. J Environ Pathol Toxicol Oncol 2002; 21(2): 149-153.
12. Wilkinson-Berka JL, Alousis NS, Kelly DJ, Gilbert RE. COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2003; 44(3): 974-979.
13. Abou-Issa H, Alshafie G. Celecoxib: A novel treatment for lung cancer. Expert Rev Anticancer Ther 2004; 4(5): 725-734.
14. Nix P, Lind M, Greenman J, Stafford N, Cawkwell L. Expression of Cox-2 protein in radioresistant laryngeal cancer. Ann Oncol 2004; 15(5): 797-801.
15. Chevez-Barrios P, Hurwitz MY, Louie K, Marcus KT, Holcombe VN, Schafer P et al. Metastatic and nonmetastatic models of retinoblastoma. Am J Pathol 2000; 157(4): 1405-1412.
16. Kim SH, Song SH, Kim SG, Chun KS, Lim SY, Na HK et al. Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target. J Cancer Res Clin Oncol 2004; 130(9): 551-560.
17. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 2002; 62(7): 2029-2033.
18. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. Lancet 2005; 365(9458): 475-481.
19. Takahashi K, Saishin Y, Mori K, Ando A, Yamamoto S, Oshima Y et al. Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci 2003; 44(1): 409-415.